Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR lentiviral vector (BaEV pseudotype) is a gene therapy tool designed to engineer cells to express a chimeric antigen receptor (CAR) targeting the CD19 antigen. This specific vector is pseudotyped with the Baboon envelope (BaEV) glycoprotein, which utilizes the ASCT1 and ASCT2 neutral amino acid transporters as entry receptors. This pseudotyping strategy is intended to overcome the limitations of standard VSV-G pseudotyped vectors, particularly in the transduction of quiescent or hard-to-transduce cells like hematopoietic stem cells (HSCs) and resting T cells. Developed by researchers associated with Miltenyi Biotec, the vector is optimized for use in automated, closed-system manufacturing platforms like the CliniMACS Prodigy to enhance the scalability and standardization of CAR-based therapies for B-cell malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CD19 CAR lentiviral vector (BaEV pseudotype).